Lazorin nasal spray 1.18 mg/ml. 10 ml.

Description

Lazorin Storage:

active substance: tramazoline;

1 ml of solution contains tramazoline hydrochloride monohydrate 1,265 mg, which corresponds to 1.18 mg of tramazoline hydrochloride;

Excipients: citric acid monohydrate, sodium hydroxide, benzalkonium chloride, hydroxypropylmethylcellulose, povidone, glycerin (85%), magnesium sulfate heptahydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, sodium chlorocarbonate, sodium, hydrocarbonate, sodium.

Lazorin Dosage form

Nasal spray.

Main physical and chemical properties: clear, slightly yellowish solution with the smell of eucalyptus.

Lazorin Pharmacotherapeutic group.

Anti-edema and other topical agents for diseases of the nasal cavity. Sympathomimetics, simple drugs.

ATX code R01A A09.

Lazorin Pharmacological properties.

Pharmacodynamics.

Tramazoline is a derivative of imidazoline. Tramazoline is an α-sympathomimetic that directly excites α-adrenergic receptors in the sympathetic nervous system, but has little or no effect on b-adrenergic receptors. Intranasal administration of tramazoline leads to narrowing of dilated arterioles, which reduces blood circulation in the mucous membrane, reduces edema and improves nasal breathing.

After intranasal administration of the drug vasoconstriction occurs in 5 minutes and lasts 8-10 hours.

Pharmacokinetics.

No human pharmacokinetic studies have been performed. The pharmacokinetic characteristics of tramazoline were studied in rats, rabbits and primates. It was found that 50-80% of the dose is absorbed by oral and intranasal administration.

Tramazoline and its metabolites are distributed to all internal organs. The highest concentrations are always observed in the liver.

Following oral and topical administration, three major metabolites were detected in the urine.

The terminal half-life of tramazoline and its metabolites in the blood is 5-7 hours.

Tramazoline and its metabolites are excreted primarily by the kidneys.

Following intranasal administration, the amount of drug absorbed may sometimes be sufficient to cause systemic manifestations that affect, in particular, the central nervous and cardiovascular systems.

Clinical characteristics.

Indication.

To relieve nasal congestion associated with acute rhinitis, vasomotor rhinitis and allergic rhinitis.

To facilitate the secretion of sinusitis and otitis media associated with acute rhinitis.